Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomy.
#BladderCancer
#blcsm
#uroonc
#utuc
bladder urothelial carcinoma
prognosis
radical cystectomy
survival
variant histology
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
medline:
23
10
2023
pubmed:
8
2
2023
entrez:
7
2
2023
Statut:
ppublish
Résumé
To evaluate variant histologies (VHs) for disease-specific survival (DSS) in patients with invasive urothelial bladder cancer (BCa) undergoing radical cystectomy (RC). We analysed a multi-institutional cohort of 1082 patients treated with upfront RC for cT1-4aN0M0 urothelial BCa at eight centres. Univariable and multivariable Cox' regression analyses were used to assess the effect of different VHs on DSS in overall cohort and three stage-based analyses. The stages were defined as 'organ-confined' (≤pT2N0), 'locally advanced' (pT3-4N0) and 'node-positive' (pTanyN1-3). Overall, 784 patients (72.5%) had pure urothelial carcinoma (UC), while the remaining 298 (27.5%) harboured a VH. Squamous differentiation was the most common VH, observed in 166 patients (15.3%), followed by micropapillary (40 patients [3.7%]), sarcomatoid (29 patients [2.7%]), glandular (18 patients [1.7%]), lymphoepithelioma-like (14 patients [1.3%]), small-cell (13 patients [1.2%]), clear-cell (eight patients [0.7%]), nested (seven patients [0.6%]) and plasmacytoid VH (three patients [0.3%]). The median follow-up was 2.3 years. Overall, 534 (49.4%) disease-related deaths occurred. In uni- and multivariable analyses, plasmacytoid and small-cell VHs were associated with worse DSS in the overall cohort (both P = 0.04). In univariable analyses, sarcomatoid VH was significantly associated with worse DSS, while lymphoepithelioma-like VH had favourable DSS compared to pure UC. Clear-cell (P = 0.015) and small-cell (P = 0.011) VH were associated with worse DSS in the organ-confined and node-positive cohorts, respectively. More than 25% of patients harboured a VH at time of RC. Compared to pure UC, clear-cell, plasmacytoid, small-cell and sarcomatoid VHs were associated with worse DSS, while lymphoepithelioma-like VH was characterized by a DSS benefit. Accurate pathological diagnosis of VHs may ensure tailored counselling to identify patients who require more intensive management.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
170-180Informations de copyright
© 2023 BJU International.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin 2021; 71: 7-33
Witjes JA, Bruins HM, Cathomas R et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol 2021; 79: 82-104
Yu EY, Liu Y, Chen Y et al. The effects of the interaction of genetic predisposition with lifestyle factors on bladder cancer risk. BJU Int 2022. https://doi.org/10.1111/bju.15880
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO classification of Tumours of the urinary system and male genital organs-Part B: Prostate and bladder Tumours. Eur Urol 2016; 70: 106-19
Lobo N, Shariat SF, Guo CC et al. What is the significance of variant histology in urothelial carcinoma? Eur Urol Focus 2020; 6: 653-63
Mori K, Abufaraj M, Mostafaei H et al. A systematic review and meta-analysis of variant histology in urothelial carcinoma of the bladder treated with radical cystectomy. J Urol 2020; 204: 1129-40
Veskimäe E, Espinos EL, Bruins HM et al. What is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol 2019; 2: 625-42
Mnatzaganian G, Davidson DC, Hiller JE, Ryan P. Propensity score matching and randomization. J Clin Epidemiol 2015; 68: 760-8
Moschini M, Dell'Oglio P, Luciano R et al. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. Urol Oncol 2017; 35: 335-41
Stroman L, Nair R, Russell B et al. The impact of non-urothelial variant histology on oncological outcomes following radical cystectomy. BJU Int 2019; 124: 418-23
Xylinas E, Rink M, Robinson BD et al. Impact of histological variants on oncological outcomes of patients with urothelial carcinoma of the bladder treated with radical cystectomy. Eur J Cancer 2013; 49: 1889-97
Williamson SR, Zhang S, Lopez-Beltran A et al. Lymphoepithelioma-like carcinoma of the urinary bladder: Clinicopathologic, immunohistochemical, and molecular features. Am J Surg Pathol 2011; 35: 474-83
Yang AW, Pooli A, Lele SM, Kim IW, Davies JD, LaGrange CA. Lymphoepithelioma-like, a variant of urothelial carcinoma of the urinary bladder: A case report and systematic review for optimal treatment modality for disease-free survival. BMC Urol 2017; 17: 34
Monn MF, Kaimakliotis HZ, Cary KC et al. The changing reality of urothelial bladder cancer: Should non-squamous variant histology be managed as a distinct clinical entity? BJU Int 2015; 116: 236-40
Scosyrev E, Ely BW, Messing EM et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of southwest oncology group-directed intergroup study (S8710). BJU Int 2011; 108: 693-9
Necchi A, Raggi D, Gallina A et al. Updated results of PURE-01 with preliminary activity of Neoadjuvant Pembrolizumab in patients with muscle-invasive bladder carcinoma with variant Histologies. Eur Urol 2020; 77: 439-46
Naspro R, Finati M, Roscigno M et al. The impact of histological variants on outcomes after open radical cystectomy for muscle-invasive urothelial bladder cancer: Results from a single tertiary referral Centre. World J Urol 2021; 39: 1917-26
Sui W, Matulay JT, Onyeji IC et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol 2017; 35: 1055-61
Lawrentschuk N. Centralisation of complex urological surgery and understanding the three Es: Is it inevitable? BJU Int 2021; 128(Suppl 1): 4-5
Sui W, Hall ME, Barocas DA et al. Association between surgical volume and survival among patients with variant Histologies of bladder cancer. Urology 2022; 159: 100-6
Martini A, Afferi L, Zamboni S et al. Oncologic surveillance for variant histology bladder cancer after radical cystectomy. J Urol 2021; 206: 885-93
Fu M, Klose C, Sparks A, Whalen M. Impact of variant histology on occult nodal metastasis after Neoadjuvant chemotherapy for muscle-invasive bladder cancer: A review of the National Cancer Database. Clin Genitourin Cancer 2022; 20: e135-9
Kim DK, Kim JW, Ro JY et al. Plasmacytoid variant urothelial carcinoma of the bladder: A systematic review and meta-analysis of clinicopathological features and survival outcomes. J Urol 2020; 204: 215-23
Warrick JI. Clinical significance of histologic variants of bladder cancer. JNCCN J Natl Compr Cancer Netw 2017; 15: 1268-74
Reis H, Serrette R, Posada J et al. PD-L1 expression in urothelial carcinoma with predominant or pure variant histology: Concordance among 3 commonly used and commercially available antibodies. Am J Surg Pathol 2019; 43: 920-7
Shen P, Jing Y, Zhang R et al. Comprehensive genomic profiling of neuroendocrine bladder cancer pinpoints molecular origin and potential therapeutics. Oncogene 2018; 37: 3039-44
Lynch SP, Shen Y, Kamat A et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: Results from a retrospective study at the md Anderson cancer center. Eur Urol 2013; 64: 307-13
Wang G, Xiao L, Zhang M et al. Small cell carcinoma of the urinary bladder: A clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol 2018; 79: 57-65
Mai KT, Bateman J, Djordjevic B, Flood TA, Belanger EC. Clear cell urothelial carcinoma: A study of 10 cases and meta-analysis of the entity. Evidence of mesonephric differentiation. Int J Surg Pathol 2017; 25: 18-25
Deuker M, Martin T, Stolzenbach F et al. Bladder cancer: A comparison between non-urothelial variant histology and urothelial carcinoma across all stages and treatment modalities. Clin Genitourin Cancer 2021; 19: 60-68.e1
Kimura S, Mari A, Foerster B et al. Prognostic value of concomitant carcinoma In situ in the radical cystectomy specimen: A systematic review and meta-analysis. J Urol 2019; 201: 46-53
Zhang L, Wu B, Zha Z, Zhao H, Yuan J, Jiang Y. Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: A PRISMA-compliant systematic review and meta-analysis. World J Urol 2020; 38: 129-42
Warrick JI, Sjödahl G, Kaag M et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur Urol 2019; 75: 18-22